Reasons why Recursion Pharmaceuticals Inc’s (NASDAQ:RXRX) fundamentals are futile

The price of Recursion Pharmaceuticals Inc (NASDAQ:RXRX) shares last traded on Wall Street fell -7.86% to $5.63.

RXRX stock price is now -21.54% away from the 50-day moving average and -29.91% away from the 200-day moving average. The market capitalization of the company currently stands at $1.19B.

With the price target of $8, Morgan Stanley recently initiated with Equal-Weight rating for Recursion Pharmaceuticals Inc (NASDAQ: RXRX).

In other news, Gibson Christopher, Chief Executive Officer sold 37,177 shares of the company’s stock on Nov 01. The stock was sold for $193,306 at an average price of $5.20. Upon completion of the transaction, the Chief Executive Officer now directly owns 836,820 shares in the company, valued at $4.71 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Nov 01, Chief Executive Officer Gibson Christopher sold 25,000 shares of the business’s stock. A total of $127,995 was realized by selling the stock at an average price of $5.12. Insiders disposed of 1,776,261 shares of company stock worth roughly $10.0 million over the past 1 year. A total of 34.61% of the company’s stock is owned by insiders.

A candlestick chart of Recursion Pharmaceuticals Inc (NASDAQ: RXRX) showed a price of $6.15 on Wednesday morning. During the past 12 months, Recursion Pharmaceuticals Inc has had a low of $4.54 and a high of $16.75. As of last week, the company has a debt-to-equity ratio of 0.11, a current ratio of 3.72, and a quick ratio of 3.72. The fifty day moving average price for RXRX is $7.18 and a two-hundred day moving average price translates $8.03 for the stock.

The latest earnings results from Recursion Pharmaceuticals Inc (NASDAQ: RXRX) was released for Jun, 2023. According to the Biotechnology Company, earnings per share came in at -$0.38, missing analysts’ expectations of -$0.37 by -0.01. This compares to -$0.38 EPS in the same period last year. The net profit margin was -520.12% and return on equity was -57.36% for RXRX. The company reported revenue of $11.02 million for the quarter, compared to $7.67 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 43.56 percent. For the current quarter, analysts expect RXRX to generate $12.87M in revenue.

Recursion Pharmaceuticals Inc(RXRX) Company Profile

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 1b/2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer; REC-64151 for the treatment of immune checkpoint resistance; and Anti-PD-(L)1, an orally bioavailable small molecule to improve sensitivity to immune checkpoint inhibitors in non-small cell lung cancer and additional tumors. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Chromaderm, Inc.; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

Related Posts